Toutes les études
RecrutementPHASE3INTERVENTIONNEL

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

This research study is testing a new medication called Eloralintide (also known as LY3841136). It's designed for adults who are overweight or have obesity but do not have type 2 diabetes. The main goal is to find out if Eloralintide can effectively help people manage their weight and if it's safe to use. Some people will receive Eloralintide, while others will receive a placebo (a dummy treatment). The study has two parts: a main phase lasting about 75 weeks, and an extended phase for those with prediabetes, which will continue for another two years. This helps researchers understand the longer-term effects of the medication.

En un coup d'œil

Statut
Recrutement
Phase
PHASE3
Sponsor
Eli Lilly et Compagnie
Objectif d'inscription
1,980
Démarrer
06 Feb 2026
Achèvement estimé
01 Jul 2030

De quoi parle cette étude ?

This study is designed to investigate a new medication called Eloralintide. It's for adults who are overweight or have obesity and are looking for help with weight management, but importantly, they mustn't have type 2 diabetes. The scientists running this study want to learn two main things: first, how well Eloralintide works to help people lose weight, and second, if it's safe to use.

To do this, some people in the study will be given Eloralintide, while others will receive a placebo. A placebo looks just like the study drug but doesn't contain any active medicine. This comparison is important because it helps researchers understand if any changes are truly due to the Eloralintide or if they might have happened anyway. The study is divided into a main phase and an extension phase to get a full picture of the medication's effects.

Finding new ways to manage weight is important for many people, as being overweight or having obesity can sometimes lead to other health problems. This research could help us understand if Eloralintide could be a new option for individuals in the future.

Points clés

  • Tests a new weight-loss medication called Eloralintide.
  • For adults who are overweight or have obesity, but without type 2 diabetes.
  • Compares Eloralintide against a placebo (dummy treatment).
  • Study lasts about 75 weeks, with an optional extension for some.
  • Aims to check both how well it works and if it's safe.
  • Regular health checks throughout your participation.

Qui peut être éligible ?

To join this study, you need to be an adult (18 or older) and fit certain health measurements. For instance, your Body Mass Index (BMI) needs to be 30 or higher. If your BMI is 27 or higher, you could also qualify if you have one of these weight-related health conditions: high blood pressure, unhealthy cholesterol levels, sleep apnea (where you stop breathing briefly during sleep), or heart disease. You also need to have tried to lose weight with diet changes before and your weight must have been stable for the three months leading up to the study.

However, some things would mean you can't take part. This includes having had or planning to have weight-loss surgery (like liposuction is okay if it was over a year ago). Similarly, if you've had certain procedures inside your gut for weight loss, you might not be eligible. You also can't have type 1 or type 2 diabetes. If you've had a recent heart attack, stroke, or other serious heart problems in the last three months, or severe heart failure, you won't be able to join. Finally, if you've used other weight-loss medications or remedies in the last three months, you won't qualify.

Cet étude pourrait-elle vous convenir ?

Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.

  1. Avez-vous 18 ans ou plus ?
  2. Is your Body Mass Index (BMI) 30 or higher, or 27 or higher with conditions like high blood pressure or sleep apnea?
  3. Have you tried to lose weight through dieting before?
  4. Have you had stable weight for the past 3 months?
  5. Do you NOT have type 1 or type 2 diabetes?
  6. Have you NOT had any major heart problems (like a heart attack or stroke) in the past 3 months?
Répondez à chaque question pour voir votre résultat.

En quoi consiste la participation ?

If you decide to take part in this study, you'll be involved for about 75 weeks, which is roughly a year and a half. During this time, you'll have regular visits to the study clinic where doctors and nurses will check your health, measure your weight, and ask about your well-being. You'll be given either the study medication (Eloralintide) or a placebo, which you'll need to take as instructed.

For some participants who have 'prediabetes' (meaning their blood sugar levels are higher than normal but not yet at the level of type 2 diabetes), the study will continue for an extra two years after the main phase finishes. This 'extension phase' will help researchers understand the long-term effects of the medication in this specific group. Throughout the study, you'll be actively monitored, and you'll have scheduled appointments to ensure your safety and to track your progress.

Risques et avantages potentiels

Taking part in any medical study has potential benefits and risks. A potential benefit of joining this study could be receiving a new medication that might help you manage your weight. You’ll also receive regular medical check-ups and monitoring by a healthcare team. However, there are potential risks, such as experiencing side effects from the study medication, though these are carefully monitored. It's also possible that the medication might not work for you, or that you could receive the placebo. Your health and safety are paramount, and you are free to withdraw from the study at any time, for any reason, without affecting your usual medical care.

Locations (158)

  • MFA Clinical Research
    Code postal vérifié
    Tuscaloosa, United States· Recrutement
  • Headlands Research - Scottsdale
    Code postal vérifié
    Scottsdale, États-Unis· Recrutement
  • Institut de Santé du Quartier
    Code postal vérifié
    Escondido, États-Unis· Recrutement
  • Ark Recherche Clinique - Fountain Valley
    Code postal vérifié
    Fountain Valley, États-Unis· Recrutement
  • Desert Oasis Healthcare Medical Group
    Code postal vérifié
    Palm Springs, United States· Recrutement
  • Peninsula Research Associates
    Code postal vérifié
    Rolling Hills Estates, United States· Recrutement
  • Care Access - Sacramento
    Code postal vérifié
    Sacramento, États-Unis· Recrutement
  • Southern California Clinical Research
    Code postal vérifié
    Santa Ana, United States· Recrutement
  • University Clinical Investigators, Inc.
    Code postal vérifié
    Tustin, United States· Recrutement
  • Chase Medical Research, LLC
    Code postal vérifié
    Waterbury, United States· Recrutement
  • JEM Research Institute
    Code postal vérifié
    Atlantis, United States· Recrutement
  • BioMed Research & Medical Center
    Code postal vérifié
    Miami, États-Unis· Recrutement

Questions fréquentes

What is Eloralintide?

Eloralintide is a new medication being tested in this study to see if it can help adults who are overweight or have obesity manage their weight.

Qu'est-ce qu'un 'placebo' ?

A placebo is a 'dummy' treatment that looks just like the real medication but contains no active ingredients. It's used so researchers can compare its effects to the actual drug.

How long will the study last if I join?

The main part of the study will last about 75 weeks (around 1.5 years). If you have prediabetes, you might continue for another 2 years in an extension phase.

Can I join if I have diabetes?

No, this study is specifically for people who do not have type 1 or type 2 diabetes.

Will I know if I'm getting the real medication or the placebo?

No, during the study, neither you nor your study doctor will know whether you are receiving Eloralintide or the placebo. This is to ensure fair and unbiased results.

Comment en savoir plus

Trial question or participation questions: 1-877-CTLILLY (1-877-285-4559) or

Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.

Intéressé à participer ?

Inscrivez votre intérêt

Partagez vos coordonnées et l'équipe de recherche pour "A Study of Eloralintide (LY3841136) in Participants With Obe… vous contactera si vous êtes éligible. Consultez toujours votre médecin avant d'accepter de participer.

Discussion

Discussion communautaire

Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.